跳至主要内容
临床试验/CTRI/2019/07/020234
CTRI/2019/07/020234尚未招募2 期

Study of Efficacy and Safety of add on Apremilast in patients with Unstable Vitiligo.

AIIMS JODHPUR0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
AIIMS JODHPUR

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Subjects with non-segmental, unstable vitiligo.
  • 2)Unstable vitiligo: Occurrence of new patch/progression of existing patch/presence of Koebner phenomenon in cases with vitiligo for 6 months.
  • 3) In general good health (except vitiligo), based on medical history, physical examination.

排除标准

  • 1. Clinically significant (as determined by the clinician) or other major uncontrolled diseases that will affect the health of the subject during the study or interfere with the interpretation of study results (such as migraine/IBD/IBS etc).
  • 2. Cases with only acrofacial vitiligo.
  • 3. Pregnant & Breastfeeding females.
  • 4. Any known allergy with apremilast.
  • 5. Cases on any drug with pigmentation potential.

研究者

发起方
AIIMS JODHPUR

相似试验